CYFRA 21-1 (Cytokeratin 19 Fragment), Serum
Also known as: CYFRA
Use
CYFRA 21-1 (Cytokeratin 19 Fragment) is used for prognostication and monitoring in non-small cell lung carcinoma (NSCLC). It assists in evaluating disease status and therapeutic efficacy. The assay measures the fragment levels in serum, providing valuable insight into tumor activity.
Special Instructions
This test is specifically approved by the state of New York. When collecting specimens, ensure that the blood is collected in a plain red or serum separator tube, and handle as per instructions to maintain sample integrity.
Limitations
The CYFRA 21-1 assay cannot be used as absolute evidence for the presence or absence of malignant disease. Variability between different assays means results from different methods or kits are not interchangeable, and the test should be used as part of a comprehensive diagnostic approach.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 25390-6
- 25390-6
Result Turnaround Time
1-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Allow serum specimen to clot completely at room temperature. Separate serum from cells ASAP or within 2 hours of collection. Transfer required volume to the transport tube.
Causes for Rejection
Plasma. Icteric, lipemic, or hemolyzed specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 2 months (avoid repeated freeze/thaw cycles) |